Compelo Packaging - Latest industry news and analysis is using cookies

ContinueLearn More

Recipharm commissions new blow-fill-seal machinery at French facility

Swedish contract development and manufacturing organization (CDMO) Recipharm has completed blow-fill-seal expansion at its facility in Kaysersberg, France.

The company made €18m investment to add a new Blow-fill-seal high-speed filling and packaging line to the site.

It increases the total number of lines to eight and boost manufacturing capacity by 200 million unidoses per year.

Recipharm said that the investment adds 2,400m² to the facility creating space for installation of three more machines. The expansion allows the site to manufacture more than 1.2 billion unidoses a year.

Recipharm Kaysersberg site general manager Yves Buelens said: “This latest investment is in direct response to customer demand for single-dose and sterile manufacturing services, such as aseptic processing for eye care and ear care products, particularly from markets such as the US, Turkey, Australia and Canada.

“This project was supported by the Region Grand Est and the CCI Alsace Eurométropole as part of employment-related actions.”

“Adding the line to our facility will allow us to take on new customer projects more quickly, as well as continue to meet our current customers’ requirements. The additional space we’ve added also means we are also well positioned for further growth in line with future customer demand.”

The filling lines will allow Recipharm to provide aseptic processing of sterile liquids including eye care and ear drops into plastic containers for drug developers.

In addition to manufacturing single dose units, the Kaysersberg specializes in blow-fill-seal technology for sterile liquids. The site features an advanced aseptic process for sterile liquid packaging applications in plastic containers.

Recipharm, which employs about 5,000 people, provides manufacturing services of pharmaceuticals in several dosage forms, production of clinical trial material and APIs and pharmaceutical product development.